#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cystic fibrosis lung Rectal cancer Cutaneous T-cell lymphoma Narcolepsy Follicular lymphoma stage II Bulbospinal muscular atrophy congenital Immunodeficiency congenital Wolfram syndrome Kaposi's sarcoma Lymphatic malformation Pulmonary tuberculosis Gastroenteropancreatic neuroendocrine tumour disease Marginal zone lymphoma refractory Alagille syndrome Chronic cutaneous lupus erythematosus More trials…

    Learn about Rare Diseases

    Erdheim-Chester disease – Basic Information Lymphangioma Pelizaeus-Merzbacher disease – Treatment Medulloblastoma recurrent – Treatment Idiopathic pulmonary fibrosis – Treatment Immunodeficiency congenital – Life with Disease Langerhans’ cell histiocytosis – Life with Disease Vascular malformation – Trials in Disease Indolent systemic mastocytosis – Diagnostics Systemic mastocytosis More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Emavusertib Tianeptine Sodium Folic Acid Msv-Allo Epinephrine Letrozole Ciprofloxacin Hydrochloride Furosemide Ph. Eur. ORX750 Hypothalamic Phospholipids IM-101 Vesleteplirsen Ripretinib Alternaria Alternata (402) Cat Epithelium Extract Gandotinib Cipaglucosidase Alfa Dexamethasone Isonicotinate Citric Acid Monohydrate Aluminium Oxide More therapies…

    Learn about Your Condition

    Metastasis Synovitis Rhinitis allergic Endometrial cancer recurrent Ischaemic stroke Cardiac failure Aortic disorder Aplasia pure red cell Squamous cell carcinoma Cough Deafness Radicular pain Brain abscess Asymptomatic HIV infection Petit mal epilepsy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2zz Bqkkcrofz Df Syhbjc Mhngzytyxrs Bs 1wam Mbqqbaoaga 1xuiry Fqvwkh

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Reducing Treatment for Stage IIa/IIb Seminoma Using Etoposide, Cisplatin, and Carboplatin in Patients with Tumors Smaller than 3 cm

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Etoposide
    France

  • Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Peritoneal cancer index
    • Fallopian tube cancer
    • Ovarian cancer
    Investigated Drugs:
    • Dostarlimab
    • Bevacizumab
    • Doxorubicin Hydrochloride
    Czechia France Germany Italy

  • Title: Study of TAR-0520 gel for skin rash (folliculitis) caused by cancer treatment with EGFR inhibitors in colorectal cancer patients

    Recruiting

    2 1
    Investigated Drugs:
    • Brimonidine Tartrate
    France

  • Study of Capecitabine and Pembrolizumab for Patients with Triple Negative Breast Cancer After Chemoimmunotherapy and Surgery

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Pembrolizumab
    France

  • Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    • Breast cancer metastatic
    Investigated Drugs:
    • Eribulin Mesylate
    • Zanidatamab
    • Capecitabine
    Austria Belgium France Germany Greece Italy +2

  • Study on the Effectiveness of Doxorubicin, Ifosfamide, and Dacarbazine in High-Risk Patients with Resectable Soft-Tissue Sarcoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Soft tissue sarcoma
    Investigated Drugs:
    • Ifosfamide
    • Dacarbazine
    • Doxorubicin Hydrochloride
    France

  • Study on the Safety and Effects of Farletuzumab Ecteribulin for Patients with Ovarian, Breast, Endometrial, and Lung Cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    • Non-small cell lung cancer
    • Ovarian cancer
    Investigated Drugs:
    • Farletuzumab Ecteribulin
    • Lenvatinib
    France Spain

  • Study on MB-CART2019.1 for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible for High-Dose Chemotherapy and Stem Cell Transplantation

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Bendamustine Hydrochloride
    • Gemcitabine Hydrochloride
    • Oxaliplatin
    Austria Belgium Croatia Czechia Finland France +9

  • Study Comparing Survival in Patients with Advanced or Metastatic Gastric Cancer Treated with Botensilimab and Balstilimab vs. Standard Drug Combination

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastric cancer
    Investigated Drugs:
    • Balstilimab
    • Botensilimab
    • Capecitabine
    France

  • Study on the Safety of Using Chemoradiation with Cisplatin and Carboplatin for Early-Stage Vulvar Cancer Patients with Macrometastasis in Sentinel Lymph Node

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Vulval cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    Belgium France The Netherlands Sweden
Previous Page
1 … 9 10 11 12 13 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!